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Abstract
Background: Widespread abnormalities in white matter development are frequently reported in cases of autism
spectrum disorders (ASD) and could be involved in the disconnectivity suggested in these disorders. Homozygous
mutations in the gene coding for fatty-acid 2-hydroxylase (FA2H), an enzyme involved in myelin synthesis, are
associated with complex leukodystrophies, but little is known about the functional impact of heterozygous FA2H
mutations. We hypothesized that rare deleterious heterozygous mutations of FA2H might constitute risk factors for
ASD.
Methods: We searched deleterious mutations affecting FA2H, by genotyping 1256 independent patients with ASD
genotyped using Genome Wide SNP arrays, and also by sequencing in independent set of 186 subjects with ASD
and 353 controls. We then explored the impact of the identified mutations by measuring FA2H enzymatic activity
and expression, in transfected COS7 cells.
Results: One heterozygous deletion within 16q22.3-q23.1 including FA2H was observed in two siblings who share
symptoms of autism and severe cognitive impairment, axial T2-FLAIR weighted MRI posterior periventricular white
matter lesions. Also, two rare non-synonymous mutations (R113W and R113Q) were reported. Although predictive
models suggested that R113W should be a deleterious, we did not find that FA2H activity was affected by
expression of the R113W mutation in cultured COS cells.
Conclusions: While our results do not support a major role for FA2H coding variants in ASD, a screening of other
genes related to myelin synthesis would allow us to better understand the role of non-neuronal elements in ASD
susceptibility.
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Background
Autism spectrum disorders (ASD) are characterized by
impairments in reciprocal social interactions, language
impairments and repetitive, stereotyped and ritualistic
verbal and non-verbal behaviors. Beyond this unifying
definition lies an extreme degree of clinical heterogen-
eity, ranging from mild to profound impairments [1,2].
Some of this heterogeneity might be due to heritable
components of ASD arising from multiple independently
regulated genes. One of these mechanisms is abnormal
myelin development, which could explain the wide-
spread abnormalities in white matter development that
are thought to affect functional frontotemporal, fronto-
limbic, frontoparietal and inter-hemispheric connections
in patients with ASD [3]. Indeed, transcriptomics
coupled to pathway analyses have shown that immune-
glial genes could contribute to the disorder [4]. Further
evidence for connectivity abnormalities comes from dys-
regulation in certain genes, such as CNTNAP2 and
CNTN4, that code for proteins located at the nodes of
Ranvier that organize the tight junctions between axons
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and myelinating glia [5]. It has been hypothesized that
reduced long-range connectivity and excess local con-
nectivity may affect system-wide integration of brain ac-
tivity, which has been suggested to explain some
symptoms of autism such as poor central coherence [6].
FA2H gene codes for fatty acid 2-hydroxylase (FA2H)
[2], an enzyme that produces 2-hydroxylated fatty acids
for incorporation into 2-hydroxydihydroceramide and 2-
hydroxyceramide [7]. These ceramides, in turn, serve as
precursors for the synthesis of galactosylceramide and
sulfatides, essential lipid components of myelin sheaths.
Homozygous mutations of the FA2H gene in humans
are associated with three neurodegenerative disorders in-
volving a wide variety of symptoms: complicated spastic
paraplegia (SPG35) [8], leukodystrophy with spastic
paraparesis and dystonia [9,10], and neurodegeneration
associated with brain iron accumulation [11]. Although
little is known about the effects of heterozygous muta-
tions or deletions of FA2H, and its relations with ASD,
we hypothesized that deleterious heterozygous muta-
tions of FA2H might constitute a risk factor for this
group of disorders. Using Genome Wide SNP arrays, we
genotyped 1256 independent patients with ASD. We de-
tected one heterozygous 167.1 kb deletion within
16q22.3-q23.1 including FA2H, in two siblings who share
symptoms of autism and severe cognitive impairment,
axial T2-FLAIR weighted MRI posterior periventricular
white matter lesions. We then sequenced the FA2H gene
in 186 patients with ASD and 353 controls, finding one
non-synonymous mutation (R113W) shared by the af-
fected siblings and transmitted by the mother who may
carry a somatic mosaicism.
Methods
Sample
Nine hundred and ninety six patients from the Autism
Genome Project (www.autismgenome.org) and 260 patients
from the Paris Autism Research International Sibpair Study
(PARIS) not included in the AGP, meeting stringent quality
control (QC) criteria, were included in the study. Informa-
tion concerning the phenotypic assessment of patients en-
rolled was described previously (for details see [12] and
[13]). In brief, patients were recruited by the PARIS study
at specialized clinical centers disposed in Paris (France) and
Goteborg (Sweden). The Autism Diagnostic Interview-
Revised (ADI-R) and Autism Diagnostic Observation
Schedule (ADOS) were used for clinical evaluation and
diagnosis. In Sweden, in some cases, the Diagnostic Inter-
view for Social and Communication Disorders (DISCO-10)
was applied instead of the ADI-R. Patients were included
after a clinical and medical check-up with psychiatric and
neuropsychological examination, standard karyotyping,
fragile-X testing and brain imaging and EEG whenever pos-
sible. All patients were from Caucasian ancestry.
Ethics statement
This study was approved by the local Institutional Re-
view Board (IRB) and written inform consents were ob-
tained from all participants of the study. The local IRB
are the “Comité de Protection des Personnes” (Île-de-
France Hôpital Pitié-Salpêtrière Paris) for France; the
Sahlgrenska Academy Ethics committee, University of
Gothenburg for Sweden. Written informed consent was
obtained from all participating subjects. If the proband
was under 18 years old, the proband's consent and writ-
ten parental consent were obtained.
CNV detection and validation
Two CNV calling algorithms, QuantiSNP and PennCNV,
and the CNV viewer, SnipPeep (http://snippeep.source-
forge.net/) were used. To obtain high-confidence calls, the
CNVs identified by QuantiSNP were validated by visual in-
spection of the Log R ratio and B allele frequency values.
PennCNV was used to confirm inheritance status of the
CNV calls.
CNVs were validated by quantitative PCR (qPCR) ana-
lysis using the Universal Probe Library (UPL) system from
Roche. UPL probes and primers were designed using the
UPL assay Design center from Rochar Applied Scicence.
UPL probes were labeled with 6-FAMTM fluorescein and
the fluorescence was read with the Applied Biosystems
7500 Real-Time PCR System. Each assay was conducted in
four replicates for target region probe-set and control re-
gion probe-set. Relative levels of region dosage were deter-
mined using the comparative CT method assuming that
there were two copies of DNA in the control region. The
relative copy number for each target region was calculated
as 2-ΔΔCT with confidence interval as 2-(ΔΔCT±SD).
DNA sequencing
The genomic structure of FA2H was obtained from
http://genome.ucsc.edu/ (hg18). Primers spanning all
seven intron-exon boundaries of FA2H were designed
and used to amplify the regions of interest. Amplicons
were produced from genomic DNA, and sequencing was
performed using ABI 3730 DNA sequencer (Aplied Bio-
systems, Foster City, CA). Sequence comparison to ref-
erence sequence was performed using GenalysCarbon
2.8.2b (http://www.cng.fr).
In silico protein function analysis
Multiple in silico applications were used to predict
the functional effect of the amino acid substitutions, includ-
ing SIFT (http://sift.jcvi.org/www/SIFT_seq_submit2.html),
Polyphen-2 (http://genetics.bwh.harvard.edu/pph2/), and
SNAP (http://rostlab.org/services/snap/).
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Cloning of PCR products
Exon 2 PCR products from genomic DNA derived from
blood and buccal swabs were cloned using the Strata-
Clone™ PCR cloning kit (Agilent Technologies). To de-
termine the proportion of fragments in each PCR
reaction containing either the mutant or the wild-type
allele, DNA was isolated from single plasmid clones, an-
alyzed by restriction enzyme using NcoI (New England
Biolabs) and sequenced on an ABI 3100 genetics
analyzer.
FA2H enzyme activity assay and expression assays
Methods to measure FA2H enzyme activity were similar
to those previously described [2]. Site-directed mutagen-
esis was performed using Phusion DNA polymerase
(New England Biolabs, Ipswich, MA) and mutagenic
primers per the manufacturer’s instructions and sub-
cloned into pcDNA3 as previously described [9]. We se-
quenced the plasmid DNA twice to be absolutely sure
that the mutation was present in the construct. COS7
cells were then transfected with pcDNA3, pcDNA3-
hFA2H (WT), or pcDNA3-hFA2H (R113W). For the en-
zyme activity assay, cells were harvested 24 hours after
transfection for lipid analysis. Various ceramide species
were then quantified by liquid chromatography–mass
spectrometry and normalized to protein content. For
quantification of FA2H expression, the cells were har-
vested 24 hours after transfection and processed for
western blot analysis using an anti-FA2H antibody
(www.lsbio.com/).
Results
Molecular findings
A rare CNV is identified in the PARIS ASD patient cohort
Among the 1256 independent patients with ASD
genotyped using Illumina SNP arrays [996 from the
AGP [12] and 260 from the PARIS study [13]], we de-
tected a heterozygous 167.1 kb deletion within 16q22.3-
q23.1 [chr16: 73258900-73426000_hg18] in one patient
(AUR139_7) with autism and moderate intellectual dis-
ability (see clinical data section for details / Family 1).
This CNV, inherited from the non-affected mother (So-
cial Responsiveness Scale total score: 16: compared to a
normal value <42; [14]) was shared by his affected sib-
ling (AUR139_6) with autism and severe intellectual dis-
ability, and was absent from 5 unaffected siblings
(Figure 1). The deletion, including FA2H, MLKL and the
first two exons of RFWD3, was validated by qPCR ana-
lysis using DNA from an independent blood sample
from both parents and the proband (data not shown).
No additional rare micro-rearrangement was shared by
the two affected siblings.
Figure 1 An heterozygous FA2H deletion was identified with the Human 1 M-Duo SNP array from Illumina in the patient AUR139_7.
The heterozygous deletion, inherited from the mother and shared by an affected sibling, spans 167.1 kb on chromosome 16q22.3-q23.1, and
included FA2H, MLKL and the first two exons of RFWD3. The upper plot shows Log R Ratio (in red) and B allele frequency (in green). QuantiSNP
score is represented with a blue line and indicates the deletion size. One heterozygous deletion was previously referenced in the Database of
Genomic Variants (chr16:73304298-73370177_hg18 variation_49753) and reported in 3/2026 children from the CHOP cohort. Three patients with
developmental delay are reported in DECIPHER (https://decipher.sanger.ac.uk): two carried a deletion (ID: 1694, del chr16:73196749-
73363966_hg18; ID: 253240, chr16:71201202-88651780_hg18) and one a duplication (ID: 2564, chr16:72853856-74355880_hg18). Red bars are
deletions, and blue bars are duplications.
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We then compared our results with those reported
in databases. A similar heterozygous deletion was
previously referenced in the Database of Genomic Vari-
ants (DGV; http://projects.tcag.ca/variation/) in 3/2026
healthy children recruited at the Children's Hospital of
Philadelphia (CHOP) network (inheritance not men-
tioned). The DECIPHER database (https://decipher.
sanger.ac.uk) contains only one patient (ID: 1694) with
dysmorphism and intellectual disability/developmental
delay who carried an inherited heterozygous deletion
sharing at least 80% overlap with the deletion that we
found (Figure 1). In this case, the deletion included
FA2H (except the first exon); MLKL coding for a mixed
lineage kinase domain-like protein; RFWD3 coding for a
ring finger and WD repeat domain protein; as well as
the last exons of GLG1, which codes for a Golgi glyco-
protein. Based on the Human Gene Expression Atlas 2
from the Genomics Institute of the Novartis Research
Foundation (GNF; http://biogps.org/), only FA2H was
reported to be expressed in the brain and be associated
with cognitive dysfunctions.
An ASD-specific non-synonymous mutation in FA2H?
All FA2H exons were directly sequenced in a subset of
patients with ASD (n = 186) from the Paris study and in
controls (n = 353). Two non-synonymous variations,
R113Q and R113W, affecting the same amino-acid in
exon 2, were identified in Families 2 and Family 3 re-
spectively. No additional deleterious mutation was found
in 353 controls and on the remaining allele of FA2H in
either affected sib-pair from Family 1. In Family 2,
R113Q was shared by both affected sibs. This variant
was transmitted by the healthy mother, and detected in
one of our controls (Figure 2). In silico, the R113Q vari-
ant was predicted to be benign whatever the model of
prediction used (Polyphen-2/prediction: benign, PSIC
score difference: 0.002; SNAP/prediction: neutral, reli-
ability index: 3, expected accuracy 78%; SIFT/prediction:
tolerated, SIFT score median: 0.67 to 2.09). In contrast,
R113W was predicted to be damaging (Polyphen-2/pre-
diction: damaging, PSIC score difference: 0.992; SNAP/
prediction: non neutral, reliability index: 2, expected ac-
curacy 70%; SIFT/prediction: damaging, SIFT score me-
dian: 0.02 to 2.09). This mutation was not observed in
our control samples and in the 1000 genomes database
(http://browser.1000genomes.org/) but was reported in
0.08%(11/12985) of the individuals referenced in the Ex-
ome Variant Server (http://evs.gs.washington.edu/EVS/).
The analysis of the segregation reported that R113W
was shared by both affected siblings and inherited from
the mother in Family 3. The sequence chromatograph of
the mother showed a reduced signal for the mutation
(similar results were obtained when sequencing the for-
ward and reverse strands). To determine if this reduced
signal could be related to a somatic mosaicism, exon 2
containing a NcoI site created by the mutation was amp-
lified from DNA extracted from lymphocytes and buccal
swabs. In both tissues tested, digestion of PCR products
amplified from family members showed a lack of diges-
tion in the father, a partial digestion in both affected
children and also a low level of partial digestion in the
mother (Figure 3), suggesting partial expression. To de-
termine the proportion of fragments in each PCR reac-
tions harboring either the mutant (T) or the wild-type
(C) allele, blood DNA was isolated from single plasmid
clones, analyzed by restriction enzyme using NcoI and
sequenced. Among the 165 clones sequenced in the
mother, 113 (68.5%) contained the C allele vs. 52 (31.5%)
contained the T allele (binomial test, z = 2.96, p = 0.002),
suggesting a degree of somatic mosaicism. In her af-
fected son, used as control, we were unable to detect
any significant skewed distribution of the C allele
(n = 91, 55.8%) vs. the T allele (n = 72, 44.2%) (binomial
test, z = 0.91 , p = 0.18). The allelic distribution in the
mother differed significantly from that observed in her
son (X2 = 5.6, p = 0.02). These data suggest that the
mother in Family 3 exhibits somatic mosaicism for the
R113W mutation, which could explain the lack of cose-
gregation between the variant and autistic symptoms in
the pedigree. However, since we were unable to obtain a
second sample of blood genomic DNA of the mother,
and we did not directly measure the allele bias by quan-
titative PCR, we could not confirm these results.
The mutation does not impact FA2H enzymatic activity in
transfected COS7 cells
We then assessed the impact of the R113W mutation on
the enzymatic activity of FA2H in COS7 cells in vitro.
Liquid chromatography/mass spectrometry analysis of
COS7 cells transfected with pcDNA3-hFA2H R113W
demonstrated no significant difference in enzyme activ-
ity from WT cells (Additional file 1: Figure S1). Major 2-
hydroxy ceramide species, a product of FA2H activity,
were significantly elevated by expression of either wild
type or R113W FA2H, indicating that the mutation did
not affect catalytic activity of FA2H. In addition, western
blot analysis of COS7 cells transfected with the same
mutant or wild-type FA2H constructs demonstrated
no significant difference in overall FA2H expression
(Additional file 1: Figure S1).
Clinical information
Family 1
A 5-year-old boy (AUR139_6) was referred with his
4-year-old brother (AUR139_7) to the child psychiatry
department (Robert Debré Hospital, Paris) due to severe
developmental delay. Both of them were born at term
(39 and 40 weeks) to non-consanguineous Caucasian
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parents after uneventful pregnancies and deliveries. Both
parents reported psychiatric disorders. The father had
symptoms of anxiety in the context of schizotypal per-
sonality traits. One of the father’s brothers (among 10
siblings) might have an intellectual disability, but a direct
assessment was not possible. The mother described re-
current episodes of major depressive disorders during
the previous ten-year period. Clinical psychiatric exam-
ination yielded normal results. She had left her biological
family during childhood, and was unable to provide add-
itional information about her extended family. Of the
five additional siblings of the index cases, one had social
phobia that emerged during childhood, and two of
the others had attention-deficit/hyperactivity disorder
(ADHD).
Birth weight and length of both index patients were in
the normal range, but occipitofrontal head circumfer-
ence (OFC) of both siblings was > 1 standard deviation
(SD) below the mean. During early development, pedia-
tricians reported moderate hypotonia and difficulty in
establishing eye contact. Speech was severely delayed,
and neither of them had acquired functional language at
Figure 2 FA2H deleterious single nucleotide variants in our study and in literature. (A) Distribution of R113Q in Family 2 and R113W in
Family 3. In both families, mutations were shared by both affected siblings and inherited from a healthy parent. In Family 3, the sequence
chromatograph of the mother showed a reduced signal for the mutation [the size of the allele T signal (in red) in the mother was twice lower
than the signal observed in her affected children]. (B) We compared amino acid sequence conservation across species by aligning FA2H
homologs using ClustalW (http:// www.ebi.ac.uk/Tools/clustalw2/index.html). The R113 residue showed moderate conservation. (C) Localization of
R113Q/R113W mutations and other reported mutations on a schematic representation of FA2H [8-11,15-18]. Red squares represent
transmembrane domains, the purple rectangle represents the cytochrome B5-like heme-binding domain, and green rectangles represent the
catalytic domain. The D35Y mutation has been reported in patients with leukodystrophy with spastic paraparesis and dystonia [9], the R235 and
R53_I58del mutations in patients with hereditary spastic paraplegia [8], and the R154C and Y170X mutations in patients with degeneration
associated with brain iron accumulation [11]. Splice site mutations predicted to result in skipping of exons 5-7(short gray line) and 2-7(long grey
line) have been reported [9,15].
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time of evaluation. Both boys were diagnosed with aut-
ism according to the Autism Diagnostic Interview-
Revised (ADI-R) and the Autism Diagnostic Observation
Scale (ADOS). The youngest brother was more severely
“autistic” according to his performance on the Child-
hood Autism Rating Scale (CARS) (43 vs. 35). Cognitive
performance of both brothers as measured by the Ra-
ven’s Progressive Matrices was below the first percentile.
When examined at the time of inclusion in the study,
growth parameters were within the normal range for
both patients with the exception of the OFC, which
remained > 1 SD below the mean. The neurological
exams of both patients were normal except for moderate
localized ligament laxity. The oldest brother exhibited
minor signs of dysmorphism, with brachymetatarsia of
the 4th and 5th fingers, arachnoid fingers and widely
spaced nipples. The younger brother also displayed
minor signs of dysmorphism including a triangular face,
a high forehead, long fingers, and bilateral covovarus
feet. The brain MRI of the younger patient AUR139_7 at
9 years of age showed a mild T2-FLAIR hypersignal lo-
cated in the posterior periventricular region (Figure 4)
with no significant loss of volume. Axial diffusion-
weighted images (DWI) produced slightly elevated ap-
parent diffusion coefficient (ADC) values: 0.86 in the
frontal region and 0.9 in the parieto-occipital region
(compared to a normal value of 0.8). A brain MRI per-
formed on the older brother showed a similar hyperin-
tensity signal on the axial T2-FLAIR weighted images,
located in the posterior periventricular region. High-
resolution karyotype, fragile X testing and metabolic
screening (urine amino acids, mucopolysaccharides, or-
ganic acids) were normal in both brothers.
Family 2
The patient was a 15-year-old male, born at term after
an uneventful twin pregnancy and delivery (38th week)
to non-consanguineous Caucasian parents. The maternal
personal and family history revealed no prior instances
of mental or neurological disorders, except for a possible
post-partum depression after the twin pregnancy for
which she did not receive any treatment. The clinical
psychiatric examination produced normal results. The
father reported a general anxiety disorder that emerged
during childhood in the context of a diagnosis of ADHD.
At the time of the assessment, only the anxiety disorder
persisted. His clinical exam was normal. The older sister,
aged 17 years at the time of the assessment, did not re-
port any psychiatric disorder but had experienced an
idiopathic pubertal delay. Her clinical exam was normal
except for mild strabismus. Birth weight of the patient
was 3170 g (25th percentile), length 50 cm (49th per-
centile), and OFC 36 cm (53rd percentile). Apgar scores
were 10 and 10 at 1 and 5 min after birth. Despite nor-
mal development during infancy, including walking at
15 months, the parents reported a pronounced intoler-
ance to frustrations and noises at age 2. They also noted
a paucity of interactions accompanied by stereotyped
body movements. The patient exhibited severely delayed
speech, with first words at 4 years of age. Referred to a
psychiatric unit at the age of 5 years, he was diagnosed
with autism, based on DSM-IV and ICD-10 criteria. He
also met criteria for autism according to the ADI-R and
the Autism Diagnostic Observation Scale (ADOS)
[19,20]. Assessment of his cognitive performance with
the Raven’s Colored Progressive Matrices test indicated
that his intelligence quotient (IQ) was below the first
Figure 3 Exploration of the somatic mosaicism in the Mother. (A) Results of NcoI digestion of FA2H PCR products from DNA extracted from
lymphocytes and buccal cells. A NcoI site is created by the R113W mutation in exon 2. In both types of tissue tested, we found a lack of
digestion in the father, partial digestion in both affected children and a low level of partial digestion in the mother. (B) Percentage of clones
carrying the wild type (allele C, blue bar) and mutant alleles (allele T, red bar) as determined by cloning PCR products amplified from blood DNA
of the clinically affected patient and his unaffected mother (Family 3).
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percentile for his age. When examined at age 15 years,
his height, weight and OFC were all in the normal range,
but he had minor dysmorphic features including a long
and narrow face, arachnoid fingers and a supernumerary
nipple. The neurological exam was normal. His expres-
sive language was limited to restricted and stereotyped
sentences. His dizygotic twin sister who shared the
FA2H mutation also exhibited a severe intellectual dis-
ability with autistic features, but also displayed a severe
psychomotor delay and microcephaly. The clinical pres-
entation was very different from that of her twin brother,
and suggested a Rett syndrome. Screening of the MECP2
gene at the age of 4 years, showed a de novo deletion
(c.1126del50) in exon 3 resulting in the truncation of the
protein. None of the other members of the family car-
ried this deletion.
Family 3
A 5-year old male patient, the second child of non-
consanguineous Caucasian parents with no family his-
tory of neurodevelopmental disorders, was born at term
after uneventful pregnancy and delivery. While little in-
formation is available about his early development, at
the time of the inclusion he was diagnosed with autism
based on DSM-IV and ICD-10 criteria. He also met cri-
teria for autism according to the ADI-R. He displayed
severe intellectual disability although standard IQ assess-
ment with the Stanford-Binet test was difficult. The clin-
ical examination of the patient produced normal results
except for one small café-au-lait spot on his skin. At age
19, the patient developed generalized seizures, which
were subsequently easily controlled on topiramate. The
clinical presentation of his older sister, aged 6 years was
very similar. She also met criteria for autism and moder-
ate intellectual disability (Stanford-Binet test, full scale
IQ: 43). Her clinical physical examination was also
within the normal range with the exception of one small
café-au-lait spot on her skin. Like her brother, she devel-
oped generalized seizures at age 22 that were efficiently
controlled on topiramate. The healthy mother also had
one small café-au-lait spot on her skin.
Discussion
Recent work has shown that homozygous mutations in
FA2H can produce a variety of severely impaired neuro-
logical phenotypes. In this study, we investigated the role
of heterozygous FA2H mutations and deletions in the
development of ASD. We described two affected siblings
from our PARIS cohort with severe autism and intellec-
tual disability who present axial T2-Flair weighted MRI
posterior periventricular white matter hypersignals ac-
companied by a rare heterozygous deletion of 16q22.3-
q23.1 overlapping FA2H. No additional patients with a
CNV encompassing FA2H were identified among the
996 AGP patients with ASD [12] or the additional sam-
ple from the PARIS cohort (n = 260) (1/1256, 0.08%). In
the CHOP cohort, three out of 2026 control children ex-
hibited a heterozygous deletion of FA2H (0.15%). How-
ever, none of those children have been clinically
evaluated for the absence of autistic symptoms [21].
Nonetheless, one subject in the DECIPHER database
who carried a similar heterozygous deletion encompass-
ing FA2H had also intellectual disability and hypotonia.
Although several models predicted that R113W should
be a deleterious mutation, we did not find that this mu-
tation affected FA2H enzymatic activity as measured in
Figure 4 Brain MRI of the patient AUR139_7 at 9 years of age. (A) Axial T2-FLAIR weighted images showed slightly prolonged relaxation
times in the periventricular white matter, more prominent in the posterior region (red arrow) with no significant loss of volume. (B) Axial
diffusion-weighted images (DWI) showed slightly elevated apparent diffusion coefficient (ADC) values.
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an over expression model in vitro. This assay, however,
might have been unable to detect subtle reductions in
enzymatic activity. Among the non-synonymous dele-
terious mutations previously reported in FA2H-related
disorders, only D35Y had a striking effect on FA2H en-
zymatic activity [9]. R154C did not affect significantly
the enzyme activity when tested in a similar in vitro
model (although the mutation was involved in neurode-
generation with brain iron accumulation), and R235C
had a moderate effect when over-expressed [8]. Notably,
R113W and R154C are both located in functionally
uncharacterized regions of the FA2H protein (Figure 2)
that could explain their lack of in vitro impact (in con-
trast to D35Y and R235C located in functional domains
that have a clear in vitro impact on FA2H activity).
Based on our results, heterozygous FA2H mutations
do not seem to play a major role in the etiology of ASD.
This may be consistent with previous publications de-
scribing patients with homozygous mutations in FA2H,
which do not report an increased prevalence of autistic
or psychiatric symptoms in the relatives carrying the
heterozygous mutations. However, the role of FA2H het-
erozygous mutations as minor risk factors for ASD
would need additional considerations. Specifically, ex-
ome sequencing of the probands and their parents
would have helped to determine if additional mutations
in genes related to autism or intellectual disability or in
the same pathway than FA2H, might be involved in the
families we presented. Recent findings suggested that
co-occurrence of deleterious mutations, together with
inherited variations plays a major role in the genetic sus-
ceptibility to ASD [13,22].
Finally, the case studies described here may support
the growing consensus that proteins involved in myelin-
ation, and not only those involved in neuronal function,
might be important in the etiology of ASD [23]. A recent
post mortem study of white matter in the brains of ASD
patients revealed a decreased number of highly myelin-
ated long-distance axonal projections in the anterior cin-
gulate cortex accompanied by over-expression of
Growth Associated Protein 43 and abnormally high
numbers of thin axons involved in local connectivity
[24]. This study also reported decreased myelin thick-
ness in axons located in the orbitofrontal cortex. Ac-
cording to the hypothesis of frontal dis-connectivity in
ASD [6], altered white matter composition in anterior
cingulate cortex and orbitofrontal cortex could change
the functional relationship between prefrontal areas as
well as transmission to downstream regions. Results
from diffusion tensor imaging tractography used to
measure white matter in ASD patients also support this
hypothesis [25,26]. Specifically, ASD patients had a
smaller total white matter volume, lower fractional an-
isotropy of white matter tracts connecting the putamen
to frontal cortical areas, and higher mean diffusivity of
white matter tracts connecting the nucleus accumbens
to frontal cortex [26].
Conclusion
In summary, the evidence implicating white matter
abnormalities in ASD suggest that additional genes or
environmental factors involved in myelination take part
in the development of these disorders. A screening of
other genes related to myelin synthesis would allow us
to better understand the role of these non-neuronal ele-
ments in ASD susceptibility.
Additional file
Additional file 1: Figure S1. (A) FA2H expression in transfected COS7
cells. COS7 cells were transfected with pcDNA3, pcDNA3-hFA2H (wild
type WT), or pcDNA3-hFA2H (R113W). Cells were harvested 24 hours after
transfection and processed for Western blot. The expression of FA2H did
not appear significantly different between WT and R113W mutant. (B)
Ceramide levels in transfected COS7 cells. COS7 cells were transfected
with pcDNA3, pcDNA3-hFA2H (wild type: WT), or pcDNA3-hFA2H
(R113W). Cells were harvested 24 hours after transfection for lipid analysis.
Various ceramide species [with 2-hydroxy fatty acid (B1) or with unsubsti-
tuted fatty acid (B2)] were quantified by liquid chromatography–mass
spectrometry and normalized to protein contents. Major 2 hydroxy-
ceramide species were significantly elevated by expression of either WT
(black bars) or R113W FA2H (red bars) when compared to pcDNA3 only
(white bars), whatever the length of the fatty acid chain, indicating that
R113W mutation did not affect the catalytic activity of FA2H.
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